Thorne SH, Bartlett DL, Kirn DH: The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally?. Curr Gene Ther. 2005, 5 (4): 429-443. 10.2174/1566523054546215.
Article
CAS
PubMed
Google Scholar
Mastrangelo MJ, Eisenlohr LC, Gomella L, Lattime EC: Poxvirus vectors: orphaned and underappreciated. J Clin Invest. 2000, 105 (8): 1031-1034. 10.1172/JCI9819.
Article
CAS
PubMed
PubMed Central
Google Scholar
O'Shea CC: DNA tumor viruses -- the spies who lyse us. Curr Opin Genet Dev. 2005, 15 (1): 18-26. 10.1016/j.gde.2004.12.010.
Article
PubMed
Google Scholar
Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991, 252 (5007): 854-856. 10.1126/science.1851332.
Article
CAS
PubMed
Google Scholar
Weibel S, Raab V, Yu YA, Worschech A, Wang E, Marincola FM, Szalay AA: Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection. BMC Cancer. 2011, 11: 68-10.1186/1471-2407-11-68.
Article
CAS
PubMed
PubMed Central
Google Scholar
Worschech A, Haddad D, Stroncek DF, Wang E, Marincola FM, Szalay AA: The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunol Immunother. 2009, 58 (9): 1355-1362. 10.1007/s00262-009-0686-7.
Article
PubMed
PubMed Central
Google Scholar
Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, Marincola FM, Szalay AA: Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res. 2007, 67 (20): 10038-10046. 10.1158/0008-5472.CAN-07-0146.
Article
CAS
PubMed
Google Scholar
Sanchez-Puig JM, Sanchez L, Roy G, Blasco R: Susceptibility of different leukocyte cell types to Vaccinia virus infection. Virol J. 2004, 1: 10-10.1186/1743-422X-1-10.
Article
PubMed
PubMed Central
Google Scholar
Kelly KJ, Woo Y, Brader P, Yu Z, Riedl C, Lin SF, Chen N, Yu YA, Rusch VW, Szalay AA, et al: Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma. Hum Gene Ther. 2008, 19 (8): 774-782. 10.1089/hum.2008.036.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lin SF, Price DL, Chen CH, Brader P, Li S, Gonzalez L, Zhang Q, Yu YA, Chen N, Szalay AA, et al: Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. J Clin Endocrinol Metab. 2008, 93 (11): 4403-4407. 10.1210/jc.2008-0316.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yu Z, Li S, Brader P, Chen N, Yu YA, Zhang Q, Szalay AA, Fong Y, Wong RJ: Oncolytic vaccinia therapy of squamous cell carcinoma. Mol Cancer. 2009, 8: 45-
Article
PubMed
PubMed Central
Google Scholar
Worschech A, Chen N, Yu YA, Zhang Q, Pos Z, Weibel S, Raab V, Sabatino M, Monaco A, Liu H, et al: Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. BMC Genomics. 2009, 10: 301-10.1186/1471-2164-10-301.
Article
PubMed
PubMed Central
Google Scholar
Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ, Lababidi S, Scudiero DA, Weinstein JN, Kirsch IR: Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res. 2003, 63 (24): 8634-8647.
CAS
PubMed
Google Scholar
Weinstein JN, Pommier Y: Transcriptomic analysis of the NCI-60 cancer cell lines. C R Biol. 2003, 326 (10-11): 909-920. 10.1016/j.crvi.2003.08.005.
Article
CAS
PubMed
Google Scholar
Weinstein JN: Integromic analysis of the NCI-60 cancer cell lines. Breast Dis. 2004, 19: 11-22.
Article
CAS
PubMed
Google Scholar
Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, Kuo WL, Gwadry F, Ajay , Kouros-Mehr H, Fridlyand J, et al: Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther. 2006, 5 (4): 853-867. 10.1158/1535-7163.MCT-05-0155.
Article
CAS
PubMed
PubMed Central
Google Scholar
Weinstein JN: Spotlight on molecular profiling: "Integromic" analysis of the NCI-60 cancer cell lines. Mol Cancer Ther. 2006, 5 (11): 2601-2605. 10.1158/1535-7163.MCT-06-0640.
Article
CAS
PubMed
Google Scholar
Sabatino M, Zhao Y, Voiculescu S, Monaco A, Robbins P, Karai L, Nickoloff BJ, Maio M, Selleri S, Marincola FM, et al: Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. Cancer Res. 2008, 68 (1): 122-131. 10.1158/0008-5472.CAN-07-1939.
Article
CAS
PubMed
Google Scholar
Monsurro V, Beghelli S, Wang R, Barbi S, Coin S, Di Pasquale G, Bersani S, Castellucci M, Sorio C, Eleuteri S, et al: Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy. J Transl Med. 2010, 8: 10-10.1186/1479-5876-8-10.
Article
PubMed
PubMed Central
Google Scholar
Adams S, Robbins FM, Chen D, Wagage D, Holbeck SL, Morse HC, Stroncek D, Marincola FM: HLA class I and II genotype of the NCI-60 cell lines. J Transl Med. 2005, 3 (1): 11-10.1186/1479-5876-3-11.
Article
PubMed
PubMed Central
Google Scholar
Fernandez M, Porosnicu M, Markovic D, Barber GN: Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol. 2002, 76 (2): 895-904. 10.1128/JVI.76.2.895-904.2002.
Article
CAS
PubMed
PubMed Central
Google Scholar
Krausa P, Browning MJ: A comprehensive PCR-SSP typing system for identification of HLA-A locus alleles. Tissue Antigens. 1996, 47 (3): 237-244. 10.1111/j.1399-0039.1996.tb02547.x.
Article
CAS
PubMed
Google Scholar
Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM: High-fidelity mRNA amplification for gene profiling. Nat Biotechnol. 2000, 18 (4): 457-459. 10.1038/74546.
Article
CAS
PubMed
Google Scholar
Wang E: RNA amplification for successful gene profiling analysis. J Transl Med. 2005, 3: 28-10.1186/1479-5876-3-28.
Article
PubMed
PubMed Central
Google Scholar
Jin P, Zhao Y, Ngalame Y, Panelli MC, Nagorsen D, Monsurro V, Smith K, Hu N, Su H, Taylor PR, et al: Selection and validation of endogenous reference genes using a high throughput approach. BMC Genomics. 2004, 5 (1): 55-10.1186/1471-2164-5-55.
Article
PubMed
PubMed Central
Google Scholar
Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y: Analysis of gene expression data using BRB-ArrayTools. Cancer Inform. 2007, 3: 11-17.
PubMed
PubMed Central
Google Scholar
Seubert CM, Stritzker J, Hess M, Donat U, Sturm JB, Chen N, von Hof JM, Krewer B, Tietze LF, Gentschev I, et al: Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a beta-galactosidase-activatable prodrug seco-analog of duocarmycin SA. Cancer Gene Ther. 2011, 18 (1): 42-52. 10.1038/cgt.2010.49.
Article
CAS
PubMed
Google Scholar
Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A, Chiorini JA: Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med. 2003, 9 (10): 1306-1312. 10.1038/nm929.
Article
CAS
PubMed
Google Scholar
Strauss R, Sova P, Liu Y, Li ZY, Tuve S, Pritchard D, Brinkkoetter P, Moller T, Wildner O, Pesonen S, et al: Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res. 2009, 69 (12): 5115-5125. 10.1158/0008-5472.CAN-09-0645.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hemler ME: Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol. 2005, 6 (10): 801-811. 10.1038/nrm1736.
Article
CAS
PubMed
Google Scholar
Wickham TJ, Mathias P, Cheresh DA, Nemerow GR: Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 1993, 73 (2): 309-319. 10.1016/0092-8674(93)90231-E.
Article
CAS
PubMed
Google Scholar
Wang K, Guan T, Cheresh DA, Nemerow GR: Regulation of adenovirus membrane penetration by the cytoplasmic tail of integrin beta5. J Virol. 2000, 74 (6): 2731-2739. 10.1128/JVI.74.6.2731-2739.2000.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lyle C, McCormick F: Integrin alphavbeta5 is a primary receptor for adenovirus in CAR-negative cells. Virol J. 2010, 7: 148-10.1186/1743-422X-7-148.
Article
PubMed
PubMed Central
Google Scholar
de Parseval A, Lerner DL, Borrow P, Willett BJ, Elder JH: Blocking of feline immunodeficiency virus infection by a monoclonal antibody to CD9 is via inhibition of virus release rather than interference with receptor binding. J Virol. 1997, 71 (8): 5742-5749.
CAS
PubMed
PubMed Central
Google Scholar
Loffler S, Lottspeich F, Lanza F, Azorsa DO, ter Meulen V, Schneider-Schaulies J: CD9, a tetraspan transmembrane protein, renders cells susceptible to canine distemper virus. J Virol. 1997, 71 (1): 42-49.
CAS
PubMed
PubMed Central
Google Scholar
Sanjabi S, Hoffmann A, Liou HC, Baltimore D, Smale ST: Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages. Proc Natl Acad Sci USA. 2000, 97 (23): 12705-12710. 10.1073/pnas.230436397.
Article
CAS
PubMed
PubMed Central
Google Scholar